Urogen Pharma (NASDAQ:URGN) Given New $56.00 Price Target at Guggenheim

Urogen Pharma (NASDAQ:URGN) had its price objective decreased by investment analysts at Guggenheim from $58.00 to $56.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s price objective would suggest a potential upside of 109.32% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Oppenheimer set a $60.00 price objective on Urogen Pharma in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Urogen Pharma in a report on Monday, October 19th. Jefferies Financial Group reaffirmed a “buy” rating and set a $56.00 target price on shares of Urogen Pharma in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Thursday, October 15th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.38.

Urogen Pharma Trading Down 6.9%

Shares of NASDAQ URGN traded down $1.99 during midday trading on Thursday, reaching $26.75. The company’s stock had a trading volume of 626,533 shares, compared to its average volume of 848,285. Urogen Pharma has a one year low of $16.50 and a one year high of $50.81. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -13.46 and a beta of 1.68. The company has a 50 day moving average price of $39.60 and a 200 day moving average price of $31.46.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14). The company had revenue of $89.00 million for the quarter, compared to analysts’ expectations of $89.92 million. Research analysts anticipate that Urogen Pharma will post -0.20 earnings per share for the current fiscal year.

Insider Transactions at Urogen Pharma

In other news, insider Mark Schoenberg sold 60,677 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85. Following the transaction, the insider directly owned 59,086 shares of the company’s stock, valued at approximately $2,779,996.30. This represents a 50.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Chris Degnan sold 2,202 shares of Urogen Pharma stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the completion of the sale, the chief financial officer owned 4,561 shares of the company’s stock, valued at $167,343.09. This trade represents a 32.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 65,269 shares of company stock valued at $3,037,646. 4.80% of the stock is owned by insiders.

Institutional Trading of Urogen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of URGN. Sterling Capital Management LLC boosted its holdings in shares of Urogen Pharma by 442.1% during the 3rd quarter. Sterling Capital Management LLC now owns 1,339 shares of the company’s stock worth $54,000 after buying an additional 1,092 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Urogen Pharma by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,919 shares of the company’s stock worth $361,000 after acquiring an additional 1,165 shares during the period. Persistent Asset Partners Ltd bought a new stake in Urogen Pharma during the second quarter valued at about $66,000. Quantbot Technologies LP bought a new stake in Urogen Pharma during the second quarter valued at about $78,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Urogen Pharma in the third quarter valued at about $101,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

More Urogen Pharma News

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% from the prior quarter. The company also said repeat prescribers now make up half of ZUSDURI writers, pointing to continued commercial adoption. The Gel That Became a Business
• Positive Sentiment: The FDA accepted UroGen’s application for UGN-103, its next-generation mitomycin formulation, and set a June 14, 2027 target decision date. UroGen Q3 results and highlights
• Neutral Sentiment: UroGen reported that the first patient had been dosed in its UGN-501 Phase 1 trial, an early-stage pipeline development with no efficacy data yet. UroGen Q3 results and highlights
• Negative Sentiment: Quarterly revenue was about $89 million, slightly below analyst estimates, while the reported loss of $0.03 per share missed the consensus estimate cited in the provided coverage. The loss was narrower than a year earlier, but UroGen also cut its FY2026 guidance, raising concerns about near-term performance. UroGen stock falls on Q3 results and guidance cut

Urogen Pharma Company Profile

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.